$ACHV
ACHIEVE LIFE SCIENCES, INC.

2021 Q2 Form 10-Q Financial Statement

#000156459021043972 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q4 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.075M $2.370M $1.820M
YoY Change 14.01% 63.45% 11.66%
% of Gross Profit
Research & Development $9.227M $2.347M $1.103M
YoY Change 736.54% 33.13% -45.72%
% of Gross Profit
Depreciation & Amortization $67.00K $70.00K $70.00K
YoY Change -4.29% 16.67% 16.67%
% of Gross Profit
Operating Expenses $9.227M $2.347M $1.103M
YoY Change 736.54% 33.13% -45.72%
Operating Profit
YoY Change
Interest Expense $3.000K $20.00K $0.00
YoY Change -33.33% -100.0%
% of Operating Profit
Other Income/Expense, Net -$9.000K -$3.000K -$4.000K
YoY Change 125.0% -120.0% -110.53%
Pretax Income -$11.31M -$4.720M -$2.920M
YoY Change 287.36% 47.96% -19.34%
Income Tax
% Of Pretax Income
Net Earnings -$11.31M -$4.724M -$2.922M
YoY Change 287.1% 47.9% -19.37%
Net Earnings / Revenue
Basic Earnings Per Share -$1.53
Diluted Earnings Per Share -$1.53 -$1.103M -$1.678M
COMMON SHARES
Basic Shares Outstanding 7.391M
Diluted Shares Outstanding 7.391M

Balance Sheet

Concept 2021 Q2 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.00M $35.90M $12.10M
YoY Change 247.12% 114.97% 16.35%
Cash & Equivalents $42.00M $35.85M $12.10M
Short-Term Investments
Other Short-Term Assets $430.0K $1.100M $500.0K
YoY Change -14.0% 57.14% 25.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $42.43M $36.98M $12.70M
YoY Change 234.1% 113.31% 17.57%
LONG-TERM ASSETS
Property, Plant & Equipment $27.00K $42.00K $300.0K
YoY Change -91.0% -26.32% 322.54%
Goodwill $1.034M $1.034M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $227.0K $187.0K $500.0K
YoY Change -54.6% 0.0% 170.27%
Total Long-Term Assets $3.134M $3.323M $3.800M
YoY Change -17.53% -11.24% -3.87%
TOTAL ASSETS
Total Short-Term Assets $42.43M $36.98M $12.70M
Total Long-Term Assets $3.134M $3.323M $3.800M
Total Assets $45.57M $40.30M $16.50M
YoY Change 176.15% 91.19% 11.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $575.0K $332.0K $500.0K
YoY Change 15.0% -61.35% -29.28%
Accrued Expenses $4.095M $2.600M $1.300M
YoY Change 215.0% 30.0% -43.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.670M $2.935M $1.800M
YoY Change 159.44% 2.3% -39.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.00K $100.0K $100.0K
YoY Change -59.0% -50.0% -66.67%
Total Long-Term Liabilities $41.00K $100.0K $100.0K
YoY Change -59.0% -50.0% -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.670M $2.935M $1.800M
Total Long-Term Liabilities $41.00K $100.0K $100.0K
Total Liabilities $4.711M $3.012M $1.900M
YoY Change 147.95% -0.53% -41.56%
SHAREHOLDERS EQUITY
Retained Earnings -$79.70M -$60.43M
YoY Change 32.23%
Common Stock $120.6M $97.72M
YoY Change 53.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.85M $37.29M $14.54M
YoY Change
Total Liabilities & Shareholders Equity $45.57M $40.30M $16.50M
YoY Change 176.15% 91.19% 11.83%

Cashflow Statement

Concept 2021 Q2 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$11.31M -$4.724M -$2.922M
YoY Change 287.1% 47.9% -19.37%
Depreciation, Depletion And Amortization $67.00K $70.00K $70.00K
YoY Change -4.29% 16.67% 16.67%
Cash From Operating Activities -$9.078M -$2.480M -$2.200M
YoY Change 312.64% -27.49% -42.71%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.43M 15.94M 2.170M
YoY Change 887.74% 25.41% -53.03%
NET CHANGE
Cash From Operating Activities -9.078M -2.480M -2.200M
Cash From Investing Activities 0.000 0.000 -10.00K
Cash From Financing Activities 21.43M 15.94M 2.170M
Net Change In Cash 12.36M 13.46M -40.00K
YoY Change -30990.0% 44.89% -101.28%
FREE CASH FLOW
Cash From Operating Activities -$9.078M -$2.480M -$2.200M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$9.078M -$2.480M -$2.190M
YoY Change 314.52% -27.49% -42.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42001000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35853000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
430000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1122000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
42431000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
36975000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
37286000
achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-2000
us-gaap Share Based Compensation
ShareBasedCompensation
610000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
142000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.79
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1744014
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
us-gaap Profit Loss
ProfitLoss
-6242000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2922000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.85
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6764688
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1645426
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24000
us-gaap Net Income Loss
NetIncomeLoss
-19310000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
126000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11311000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.53
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
10000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-336000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
589000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6659000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
146000
CY2021Q2 achv Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
227000
CY2020Q4 achv Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
237000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1752000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1864000
CY2021Q2 us-gaap Goodwill
Goodwill
1034000
CY2020Q4 us-gaap Goodwill
Goodwill
1034000
CY2021Q2 us-gaap Assets
Assets
45565000
us-gaap Profit Loss
ProfitLoss
-19310000
CY2020Q4 us-gaap Assets
Assets
40298000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
575000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
332000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
193000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
584000
CY2021Q2 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
3039000
CY2020Q4 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
453000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
795000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1474000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4670000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2935000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77000
CY2021Q2 us-gaap Liabilities
Liabilities
4711000
CY2020Q4 us-gaap Liabilities
Liabilities
3012000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9452223
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9452223
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6111735
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6111735
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
79000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
76000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120515000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
97640000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79744000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60434000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40854000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
37286000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45565000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40298000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2075000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
127000
us-gaap Share Based Compensation
ShareBasedCompensation
1163000
achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
41000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-702000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
243000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-391000
achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
2585000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-680000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-381000
achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15528000
achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
-314000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7390600
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
30088000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.88
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1632370
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1632370
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
331000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40854000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18050000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3320000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
14985000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
308000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21674000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2120000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6148000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
542000
CY2021Q1 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
236000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
621000
CY2021Q2 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
95000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11311000
CY2020Q2 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
589000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2922000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
14538000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79700000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42000000.0
CY2021Q2 achv Working Capital Balance
WorkingCapitalBalance
37800000
us-gaap Net Income Loss
NetIncomeLoss
-19300000
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
112000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
223000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223000
CY2021Q2 achv Finite Lived Intangible Assets Amortization Expense After Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo
1194000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1752000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
41289000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
41289000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
achv Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
CY2020Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
227442
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
249650
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
39204.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0143
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0464
us-gaap Share Based Compensation
ShareBasedCompensation
610000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1775401
us-gaap Operating Lease Payments
OperatingLeasePayments
90000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M2D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M2D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2021Q2 us-gaap Contractual Obligation
ContractualObligation
111000
CY2021Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
35000
CY2021Q2 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
76000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
15000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
46000
us-gaap Operating Lease Payments
OperatingLeasePayments
53000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2020Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
achv Indemnification Expense
IndemnificationExpense
0

Files In Submission

Name View Source Status
0001564590-21-043972-index-headers.html Edgar Link pending
0001564590-21-043972-index.html Edgar Link pending
0001564590-21-043972.txt Edgar Link pending
0001564590-21-043972-xbrl.zip Edgar Link pending
achv-10q_20210630.htm Edgar Link pending
achv-10q_20210630_htm.xml Edgar Link completed
achv-20210630.xsd Edgar Link pending
achv-20210630_cal.xml Edgar Link unprocessable
achv-20210630_def.xml Edgar Link unprocessable
achv-20210630_lab.xml Edgar Link unprocessable
achv-20210630_pre.xml Edgar Link unprocessable
achv-ex311_7.htm Edgar Link pending
achv-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending